PolyPid PYPD 深 沪
已收盘 01-30 16:00:00 美东时间
4.58
-0.130
-2.76%
华盛通- 最 高4.7863
- 今 开4.72
- 成交量 4.33万股
- 最 低 4.52
- 昨 收 4.71
- 总市值 7618.74万
- 52周最高 5.047
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.30
- 委 比 82.16%
- 总股本 1663.48万
- 历史最高 583.50
- 量 比 0.84
- 振 幅 5.65%
- 历史最低 2.30
- 每 手 1
- 风险率 0.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026
PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, will announce its Q4 2025 financial results and operational highlights on February 11, 2026, before the U.S. market open. A conference call and webcast to discuss the results will be held at 8:30 AM Eastern Time. Registration is recommended 5 minutes prior to the call. For those not asking questions, listening via webcast is advised. The company's ...
01-28 13:00
PolyPid Appoints Brooke Story As Board Chairman, Effective Dec. 11
PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors,
2025-12-16 21:33
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
PolyPid Ltd. announced the appointment of Brooke Story as Chairman of its Board of Directors. With over 25 years of leadership experience in the MedTech industry, Story will enhance the company’s strategic, commercial, and transaction capabilities. Her expertise in surgical solutions and infection prevention will support PolyPid in advancing its lead product, D-PLEX₁₀₀, which is expected to submit its New Drug Application in early 2026. Story’s l...
2025-12-16 13:30
PolyPid Gains FDA Support for D-PLEX100 NDA Submission
An announcement from PolyPid ( ($PYPD) ) is now available. On December 3, 2025,...
2025-12-03 21:57
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission
PolyPid Ltd. has received FDA support for rolling NDA submission of D-PLEX100, its lead product for preventing surgical site infections in colorectal surgeries. The FDA agreed the company's existing clinical data, including Phase 3 results, is adequate for submission. PolyPid plans to submit the first sections in early 2026, with the Breakthrough Therapy designation further validating its regulatory strategy.
2025-12-03 13:30
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
Roth Capital Maintains Buy on PolyPid, Lowers Price Target to $9
Roth Capital analyst Boobalan Pachaiyappan maintains PolyPid (NASDAQ:PYPD) with a Buy and lowers the price target from $10 to $9.
2025-11-14 00:38
PolyPid Advances D-PLEX₁₀₀ Towards FDA Submission and Commercial Readiness
PolyPid ( ($PYPD) ) has shared an announcement. PolyPid Ltd. announced its thir...
2025-11-12 20:56
PolyPid Q3 EPS $(0.37) Beats $(0.44) Estimate
PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.44) by 15.53 percent. This is a 69.67 percent increase over losses of $(1.22) per share from the same
2025-11-12 20:30
